5―HT3受体拮抗剂在乳腺癌CEF方案化疗患者中应用价值.docVIP

5―HT3受体拮抗剂在乳腺癌CEF方案化疗患者中应用价值 　　[摘要]目的 分析5-HT3受?w拮抗剂在乳腺癌CEF方案化疗患者中的应用价值。方法 选取2014年2月～2016年11月在我院接受CEF方案化疗（含有辅助化疗及姑息化疗）的乳腺癌患者70例作为研究对象，将所有患者按照随机数字表法分为两组，各35例。两组均给予乳腺癌CEF方案化疗，观察组在化疗前30 min及化疗结束按q8h给予昂丹司琼联合地塞米松静滴，对照组仅进行CEF方案化疗，于化疗前30 min静脉滴注昂丹司琼联合地塞米松，化疗结束后不给予任何药物干预。对比两组恶心呕吐发生情况、治疗前后体力状况评分。结果 两组患者恶心呕吐总发生情况比较，差异无统计学意义（P0.05）；治疗前，两组患者体力评分分别为（88±10）、（87±9）分，两组比较，差异无统计学意义（P0.05）；治疗后，观察组体力评分为（79±10）分，明显高于对照组[（75±5）分]，差异有统计学意义（P0.05）。结论 5-HT3受体拮抗剂可有效降低乳腺癌CEF方案化疗患者出现的恶心呕吐等不良反应，根据5-HT3受体拮抗剂半衰期增加给药次数，有助于提高患者治疗依从性，并改善治疗满意度，在临床应用中值得推广。 　　[关键词]乳腺癌；CEF方案化疗；5-HT3受体拮抗剂 　　[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-4721（2017）04（b）-0087-04 　　Application value of 5-HT3 receptor antagonist in breast cancer patients with CEF chemotherapy 　　YAN Ming-ji ZHAO Peng CHEN Bing-guang 　　Department of Oncology，Yunfu People′s Hospital，Guangdong Province，Yunfu 527300，China 　　[Abstract]Objective To analyze the application value of 5-HT3 receptor antagonist in breast cancer patients with CEF chemotherapy.Methods 70 breast cancer patients received CEF chemotherapy scheme （including adjuvant chemotherapy and palliative chemotherapy） in our hospital from February 2014 to November 2016 were selected as research object，and they were divided into two groups by random number table，35 cases in each.Two groups were given breast cancer CEF chemotherapy.Observation group was given intravenous drip of Ondansetron combined with Dexamethasone before chemotherapy for 30 min and after chemotherapy，q8h.Control group was given purely CEF chemotherapy，and was given intravenous drip of Ondansetron combined with Dexamethasone before chemotherapy for 30 min，and after chemotherapy they were not given any drug intervention.The incidence of nausea and vomiting，performance status scores before and after treatment of two groups were compared.Results There was no statistical difference in the total incidence of nausea and vomiting between two groups （P0.05）；before treatment，the performance scores of two groups were （88±10），（87±9